Part,  Chapter, Paragraph

  1    I,     3.  4        |             Henkens, A. Liefbroer & H. Moors (2001), Meningen
  2   II,     4.  3        |         Montpellier, EHEMU.~ ~Kung, H., D. Hoyert, et al. (2007):
  3   II,     4.  3        |           Services: 34.~ ~Van Oyen, H., J. van der Heyden, et
  4   II,     5.  2.  6    |            B, Maheshwari N, Schrott H (2005). Pleiotropic effects
  5   II,     5.  2.  7    |            07.07).~Evans A, Tolonen H, Hense HW, Ferrario M, Sans
  6   II,     5.  2.  7    |              167:573-579.~Kesteloot H, Sans S, and Kromhout D (
  7   II,     5.  2.  7    |         Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortman S, Sans
  8   II,     5.  2.  7    |          Fortman S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto
  9   II,     5.  2.  7    |             3-10.~Sans S, Kesteloot H, Kromhout D on behalf of
 10   II,     5.  2.  7    |        Sarti C, Stegmayr B, Tolonen H, MAhonen M, Tuomilehto J,
 11   II,     5.  2.  7    |        Epidemiol14: 510-20.~Tolonen H, Mahonen M, Asplund K, rastenyte
 12   II,     5.  2.  7    |           2367-2375.~Tunstall-Pedoe H, Kuulasmaa K, Mahonen M,
 13   II,     5.  2.  7    |     Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P (
 14   II,     5.  2.  7    |             1547-57.~Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al
 15   II,     5.  3.  9    |        Boyle P, Autier P, Bartelink H, et al (2003): European
 16   II,     5.  3.  9    |             Estève J, Sant M, Storm H, Allemani C, Ciccolallo
 17   II,     5.  3.  9    |         3751.~ ~Hakama M, De Koning H (2007): Portuguese Presidency
 18   II,     5.  3.  9    |        Hédelin G, Matsuda T, Moller H, Moller T, Verdecchia A,
 19   II,     5.  3.  9    |             A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone
 20   II,     5.  5.Int(15)|       Kivela S-L, Lobo A, Magnusson H, Mann AH, Meller I, Prince
 21   II,     5.  5.  1    |     Bruffaerts R, Brugha TS, Bryson H (2004a). Prevalence of mental
 22   II,     5.  5.  3    |           Disorder 41:1 92-95.~Hoek H W, van Hoeken D, (2003):
 23   II,     5.  5.  3    |             J, Issakidis C, Lapsley H (2003): Cost-effectiveness
 24   II,     5.  5.  3    |           427-435.~Baumann A, Zäske H, Decker P, Klosterkötter
 25   II,     5.  5.  3    |             Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam
 26   II,     5.  5.  3    |              Anderson P eds.).~Fang H, Rizzo JA (2007): Do psychiatrists
 27   II,     5.  5.  3    |                     Gaebel W, Zäske H, Baumann AE, Klosterkötter
 28   II,     5.  5.  3    |       Research 3(1-2):23-33.~Häfner H and Maurer K (2006): Early
 29   II,     5.  5.  3    |       Psychiatry 5(3):130-8.~Häfner H, Maurer K, Ruhrmann S, Bechdolf
 30   II,     5.  5.  3    |              Fleischhacker W, Boter H, Davidson M, Vergouwe Y,
 31   II,     5.  5.  3    |          Hambrecht M, VON Reventlow H (2005): The European Prediction
 32   II,     5.  5.  3    |      Michels R, Malchow CP, Dilling H (2002): Comparison of psychiatric
 33   II,     5.  5.  3    |             L, Werdelin G, Karlsson H, Bjarnason O, Bengtsson-Tops
 34   II,     5.  5.  3    |             W, Buchkremer G, Häfner H, Klosterkötter J, Maier
 35   II,     5.  5.  3    |            2007.~Wrigley S, Jackson H, Judd F, Komiti A (2005):
 36   II,     5.  5.  3    |    Epilepsia 43:1402-1409.~Lindsten H, Nystrom L, Forsgren L (
 37   II,     5.  5.  3    |     Psychiatry 71:632-637.~Lindsen, H, Stenlund, H, Forsgren L (
 38   II,     5.  5.  3    |          637.~Lindsen, H, Stenlund, H, Forsgren L (2001): Remission
 39   II,     5.  5.  3    |             PE, Blom BH, Skeidsvoll H, Mykletun A (2000): Prevalence,
 40   II,     5.  5.  3    |             219-230.~Brønnum-Hansen H, Koch-Henriksen N, Hyllested
 41   II,     5.  5.  3    |           1901–1907.~Brønnum-Hansen H, Koch-Henriksen N, Stenager
 42   II,     5.  5.  3    |             844-850.~Brønnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen
 43   II,     5.  5.  3    |            Hansen T, Koch-Henriksen H (2006): Survival and mortality
 44   II,     5.  5.  3    |         Aarseth JH, Myhr KM, Nyland H, Midgard R (2004): Multiple
 45   II,     5.  5.  3    |           DeJ, Paulos A, Mendes H, et al (2006): The prevalence
 46   II,     5.  5.  3    |    Koch-Henriksen N, Brønnum-Hansen H, Hyllested K (1992): Incidence
 47   II,     5.  5.  3    |            W, Rodriguez M, Lassmann H (1996): Distinct patterns
 48   II,     5.  5.  3    |       Grytten N, Aarseth JH, Nyland H (2006): The Norwegian Multiple
 49   II,     5.  5.  3    |       Pugliatti M, Rosati G, Carton H, et al (2006): The epidemiology
 50   II,     5.  5.  3    |              McFarland HF, Hohlfeld H (eds). Multiple sclerosis.
 51   II,     5.  5.  3    |             MB, Vlietnick R, Carton H (1994): Prevalence of multiple
 52   II,     5.  5.  3    |          632.~Anderson C, Checkoway H, Franklin GM, Beresford
 53   II,     5.  5.  3    |     Poskanzer DC, Rolland C, Miller H (1966): Neurological disease
 54   II,     5.  5.  3    |         Bartalesi F, Gamboa Barahon H, Giuffrida S, Reggio A (
 55   II,     5.  5.  3    |        Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel
 56   II,     5.  5.  3    |       Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder
 57   II,     5.  6.  6    |              Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici
 58   II,     5.  6.  6    |          Silman A, Smolen J, Yazici H (2007): EULAR Recommendations
 59   II,     5.  6.  6    |             Schulenburg JM, Zeidler H, Ruof J (2005): Direct Costs
 60   II,     5.  6.  6    |         Miner Res 18:1139-1141~Merx H, Dreinhofer K, Schrader
 61   II,     5.  6.  6    |         Puhl W, Gunther KP, Brenner H (2003): International Variation
 62   II,     5.  6.  6    |         Palmer KT, Walsh K, Bendall H, Cooper C, Coggon D (2000)
 63   II,     5.  6.  6    |         Allison T, Brammah T, Busby H, Roxby M, Simmons A, Williams
 64   II,     5.  6.  6    |             84-91~Woolf AD, Zeidler H, Haglund U, Carr AJ, Chaussade
 65   II,     5.  7.  7    |        Meisinger C, Doring A, Lowel H (2006): Chronic kidney disease
 66   II,     5.  8.  7    |        Dollerup J, Baekke Borgeskov H, Lange P (2007): The cost
 67   II,     5.  8.  7    |         Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J (
 68   II,     5.  8.  7    |             MW, Schellevis FG, Raat H (2006): Prevalence estimates
 69   II,     5.  8.  7    |           IL, Nissinen A, Tukiainen H, Koskela H (2006): Thirty-year
 70   II,     5.  8.  7    |             A, Tukiainen H, Koskela H (2006): Thirty-year cumulative
 71   II,     5.  8.  7    |         2006; 130: 1129-1137.~ ~Rea H, McAuley S, Stewart A, Lamont
 72   II,     5.  8.  7    |           JB, Visick GT, Muellerova H, Payvandi N, Hansell AL (
 73   II,     5.  8.  7    |         Sunyer J, Zock JP, Kromhout H, Garcia-Esteban R, Radon
 74   II,     5.  8.  7    |            J, Kogevinas M, Kromhout H, Burney P, Antó Jm, and
 75   II,     5.  9.  7    |           Jan;42(1):60-5~ ~Schipper H, Clinch J, Olweny CLM (1990):
 76   II,     5. 10.  7    |           Strachan D, Ross Anderson H (2003): Increasing hospital
 77   II,     5. 10.  7    |        Mothes T, Troncone R, Wieser H (2001): Analysis and clinical
 78   II,     5. 11.  3    |               Source: Modified from H. Williams et al. Epidemiology
 79   II,     5. 11.  3    |           mean of hundreds of days (H Suzuki, 1998). For this
 80   II,     5. 11.  3    |            130.~T Nakada, M Iijima, H Nakayama, HI Maibach, Role
 81   II,     5. 11.  3    |              TP Dang, C Macpherson, H Maibach, HI Maibach, Prevalence
 82   II,     5. 11.  3    |       Dermatitis, 1997;37(2):78-81.~H Suzuki, Nickel and gold
 83   II,     5. 11.  7    |           Fouere S, Adjadj L, Pawin H (2005): How patients experience
 84   II,     5. 11.  7    |           HC, Pembroke AC, Forsdyke H et al (1995): London-born
 85   II,     5. 11.  7    |      Medical Press 1997.~ ~Williams H, Svensson A, Diepgen Th,
 86   II,     5. 14.  8    |      Bourgeois D, Bratthal D, Ogawa H (2005): Oral health information
 87   II,     5. 14.  8    |     Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, NDiaye
 88   II,     8.  2.  1    |             53~Fujiura, G.T., Park, H. J. and Rutkowski-Kmitta,
 89   II,     8.  2.  1    |             101-6.~Lennox N, Beange H, Davis R, et al. Management
 90   II,     8.  2.  1    |              85-90~Ouellette-Kuntz, H., (2005). Understanding
 91   II,     8.  2.  1    |              136, 903-012.~Prosser, H., Moss, S., Costello, H.,
 92   II,     8.  2.  1    |             H., Moss, S., Costello, H., Simpson, N., Patel, P., &
 93   II,     8.  2.  1    |           42 (4), 264-272.~Rimmer,J.H. (1999). health promotion
 94   II,     8.  2.  1    |              Bradley,V., Buntinx, W.H.E., Coulter, D.L., Craig,
 95   II,     8.  2.  1    |        Wehmeyer, M.L. and Yeager, M.H. (2007). The Renaming of
 96   II,     8.  2.  1    |             Straetmans, J.M.J.A.A., H.M.J. van Schrojenstein Lantman-de
 97   II,     8.  2.  1    |      Schrojenstein Lantman-de Valk, H., Buono, S., Azema, B.,
 98   II,     8.  2.  3    |        available at: htt ~ ~Fortnum H, Davis A (1997): Epidemiology
 99   II,     9            |         subjects spent at least 3.5 h per week in physical activity,
100   II,     9.  1.  1    |             3-7.~ ~Breart G, Barros H, Wagener Y, Prati S (2003):
101   II,     9.  1.  1    |           Usher RH, Kramer MS, Yang H, Morin L, Fretts RC (2000):
102   II,     9.  1.  1    |         Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
103   II,     9.  1.  1    |         Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
104   II,     9.  1.  1    |           Kramer MS, Platt RW, Yang H, Haglund B, Cnattingius
105   II,     9.  1.  1    |       Breart G, Alexander S, Barros H, Blondel B, et al (2003):
106   II,     9.  1.  2    |        medicine during pregnancy.~ ~h) More research should be
107   II,     9.  1.  2    |       References~ ~Abramsky L, Dolk H and a EUROCAT Folic Acid
108   II,     9.  1.  2    |             N, de Vigan C, de Walle H, Erickson EJ, Halliday J,
109   II,     9.  1.  2    |           693-705.~Bréart G, Barros H, Wagener Y, Prati S (2003):
110   II,     9.  1.  2    |          Busby A, Armstrong B, Dolk H, Armstrong N, Haeusler M,
111   II,     9.  1.  2    |          Bianca S, Gatt M, de Walle H, Braz P, Latos-Bielenska
112   II,     9.  1.  2    |           Busby A, Abramsky L, Dolk H, Armstrong B and a EUROCAT
113   II,     9.  1.  2    |           Busby A, Ritvanen A, Dolk H, Armstrong N, De Walle H,
114   II,     9.  1.  2    |            H, Armstrong N, De Walle H, Riano-Galan I, Gatt M,
115   II,     9.  1.  2    |            F, Calzolari E, De Walle H, Knill-Jones R, Candela
116   II,     9.  1.  2    |          Med 2007;357: 135-42.~Dolk H, Loane M, Garne E, de Walle,
117   II,     9.  1.  2    |         Loane M, Garne E, de Walle, H, Queisser-LuftA, de Vigan
118   II,     9.  1.  2    |         Gener B, Haeusler M, Jordan H, Tucker D, Stoll C, Feijoo
119   II,     9.  1.  2    |          Vol 53, pp 2S87-2S95.~Dolk H, Vrijheid, Scott JES, Addor
120   II,     9.  1.  2    |             B, de Vigan C, de Walle H, Garne E, Loane M, Pierini
121   II,     9.  1.  2    |              No 3, pp 398-402.~Dolk H, Vrijheid M (2003): "The
122   II,     9.  1.  2    |              Garne E, Loane M, Dolk H, de Vigan C, Scarano G,
123   II,     9.  1.  2    |            20:328-38.~Loane M, Dolk H, Bradbury and a EUROCAT
124   II,     9.  1.  2    |           131-7.~Schaefer C, Garbis H, McElhatton P, Reuvers M,
125   II,     9.  1.  2    |     Elsevier 2001.~Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman
126   II,     9.  3.  1    |        Bergdahl S, Lodding P, Lilja H, Hugosson J (2007): Prostate
127   II,     9.  3.  1    |              54(5): 328-332~ ~Brown H (2003): Women's Lack of
128   II,     9.  3.  1    |         practice, 62(6):973-6~ ~Lee H, McGovern K, Finkelstein
129   II,     9.  3.  2    |             3-7.~ ~Breart G, Barros H, Wagener Y, Prati S (2003):
130   II,     9.  3.  2    |           Usher RH, Kramer MS, Yang H, Morin L, Fretts RC (2000):
131   II,     9.  3.  2    |         Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
132   II,     9.  3.  2    |           Kramer MS, Platt RW, Yang H, Haglund B, Cnattingius
133   II,     9.  3.  2    |             van Dongen P, van Geijn H, Bennebroek Gravenhorst
134   II,     9.  3.  2    |       Breart G, Alexander S, Barros H, Blondel B, et al (2003):
135   II,     9.  3.  3    |      Bloemenkamp KWM, Jahn A, Karro H, Olsen J, Temmerman M on
136   II,     9.  3.  3    |             1215-23.~Layte R, McGee H, Qual A, Rundle K, Cousins
137   II,     9.  4.  4    |         subjects spent at least 3.5 h per week in physical activity,
138   II,     9.  4.  7    |          Health in Europe.~ ~Jaleel H, Allan P S, Wade A A (1999):
139   II,     9.  5.  6    |      Institute of Education~ ~Brown H (2003): Women's Lack of
140   II,     9.  5.  6    |             31 January~ ~Jernigan D H (2001): Global Status Report:
141   II,     9.  5.  6    |   Organization, Geneva~ ~Jernigan D H (2001): Global Status Report:
142  III,    10.  1.  3    |             J, Beaglehole R, Tanaka H.) New York, Oxford University
143  III,    10.  1.  3    |             J, Beaglehole R, Tanaka H.) New York, Oxford University
144  III,    10.  1.  3    |             J, Beaglehole R, Tanaka H.) New York, Oxford University
145  III,    10.  1.  3    |           174.~Kuntsche EN, Kuendig H (2006): What is worse? A
146  III,    10.  2.  1    |        Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P,
147  III,    10.  2.  1    |          Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi
148  III,    10.  2.  1    |              Zatonski W, zur Hausen H (2003): European Code Against
149  III,    10.  2.  1    |         Morleo M, Stokes E, Sumnall H, Witty K, Bellis M (2007):
150  III,    10.  2.  1    |        Drugs 20 25-40.~ ~Kristenson H, Osterling A, Nilsson JA,
151  III,    10.  2.  1    |     Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, NDiaye
152  III,    10.  2.  1    |             S, Axelsson S, Dahlgren H, Holm AK, Kallestal C, Lagerlof
153  III,    10.  2.  1    | Steingrímsdóttir, L, Þorgeirsdóttir H, Ólafsdóttir AS~Ireland~
154  III,    10.  2.  1    |            a two non-consecutive 24-h recalls (Brussard et al.,
155  III,    10.  2.  1    |         Becker W, Enghardt-Barbieri H (2004): Svenska barns matvanor
156  III,    10.  2.  1    |             in Swedish).~ ~Bendixen H, Holst C, Sørensen TIA,
157  III,    10.  2.  1    |                Branca F, Nikogosian H, Lobstein T, eds (2007a):
158  III,    10.  2.  1    |                Branca F, Nikogosian H, Lobstein T, eds (2007b):
159  III,    10.  2.  1    |             A, Stamatakis E, Wardle H (2005): Obesity among children
160  III,    10.  2.  1    |            Connell M, Yeh MC, Nawaz H, Njike V, Anderson LM, Cory
161  III,    10.  2.  1    |      Gabhainn SN, Friel S, Corrigan H, Nolan G, Sixsmith J, Walsh
162  III,    10.  2.  1    |            Kramer MS, Morin I, Yang H, Platt RW, Usher R, McNamara
163  III,    10.  2.  1    |         Platt RW, Usher R, McNamara H, Joseph KS, Wen SW (2002):
164  III,    10.  2.  1    |        Varga A, Domonkos A, Agoston H, Balázs A, Mozsáry E, Vitrai
165  III,    10.  2.  1    |                Elmadfa I, Freisling H, König J et al. Austrian
166  III,    10.  2.  1    |            Blachfelner J, Freisling H (ed.). 2nd Viennese Nutrition
167  III,    10.  2.  1    |  Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch K, Trichopoulou
168  III,    10.  2.  1    |       Thiebaut A, Miller AB, Boeing H, Kolyva M, Saieva C, Celentano
169  III,    10.  2.  4    |          Brand A, Schröder P, Brand H, Zimmern R (2006): Getting
170  III,    10.  2.  4    |        Johnson J, Cox N J, Wichmann H E, Wienker T F, Schulze
171  III,    10.  2.  4    |              Schwarz P E, Lindner T H (2007): A German genome-wide
172  III,    10.  2.  4    |       Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi
173  III,    10.  2.  4    |          Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi
174  III,    10.  2.  5    |          Luoma I, Salmelin R, Davis H, Tsiantis J, Ispanovic-Radojkovic
175  III,    10.  2.  5    |            181-91.~ ~Puura K, Davis H, Papadopoulou K, Tsiantis
176  III,    10.  3.  1    |              Sweden, (ww e)~Boegli, H., 2006. Risk assessment
177  III,    10.  3.  1    |             Barros-Dios JM, Baysson H, Bochicchio F, Deo H, Falk
178  III,    10.  3.  1    |        Baysson H, Bochicchio F, Deo H, Falk R, Forastiere F, Hakama
179  III,    10.  3.  1    |             Kempen EEMM van, Kruize H, Boshuizen HC, Ameling CB,
180  III,    10.  3.  1    |           2006) Prüss-Üstün A, Zeeb H, Mathers C, RepacholiM (
181  III,    10.  3.  2    |            et al. (2004).~ ~Barton, H.A. et al. (2005): Assessing
182  III,    10.  3.  2    |            R, Ostermann, B, Mielke, H. (2005): Rückstände von
183  III,    10.  4.  2    |              Y, Kishi, R, Nakazawa, H.(2004). Perfluorooctane
184  III,    10.  5.  1    |           exceed the recommended 24-h limit value of 50 microgram/
185  III,    10.  5.  1    |      Article. Research Support, N.I.H., Extramural. Research Support,
186  III,    10.  5.  1    |    publication No. 2/2006).~Frumkin H (2003): Healthy places:
187  III,    10.  5.  1    |         1451-1456.~Kim HS, Mccarthy H, Oren R, Finzi C, EllsWorth
188  III,    10.  5.  2    |         Health 52:487-493.~ ~Völzke H et al. (2006): Urban-rural
189  III,    10.  5.  3    |              Boedeker W, Klindworth H (2007): Hearts and minds
190  III,    10.  6.  1    |              Börsch-Supan A, Jürges H. (2005). The Survey of Health,
191  III,    10.  6.  1    |            1985.~ ~Kohb M, Künemund H, Lüdicke J. (2005): Family
192  III,    10.  6.  2    |            JJM, Lahelma E, Van Oyen H, Rasmussen NK, Regidor E,
193   IV,    11.  6.  5    |               Bartholomee Y, Maarse H (2006): "Health insurance
194   IV,    11.  6.  5    |            295.~ ~Bunker J, Frazier H et al. (1994): "Improving
195   IV,    11.  6.  5    |              189-206.~ ~Glennerster H (1997): Paying for Welfare:
196   IV,    11.  6.  5    |            Vaughan, J.P., Morrow, R.H. Manual of Epidemiology
197   IV,    12.  2        |         Type 2 diabetes a key healt h priority during its Presidency